PDCD1LG2 and classic Hodgkin lymphoma: The expression on MPS cells of two key immune checkpoints, PD-L1 and PD-L2, has been under scrutiny in cHL given the successful therapeutic targeting of their ligand PD-1 by approved immunotherapies such as nivolumab and pembrolizumab [60,61].